Diaceutics (DXRX) Full Year 2022 Results presentation - April 2023

Diaceutics CFO, Nick Roberts & CIO Ryan Keeling present full year results for the period ended 31 December 2022, which shows a strong trading performance with continued momentum driving strategic investment into 2023. Nick Roberts, CFO00:16 - Introduction01:58 - FY22 Highlights Nick Roberts, CFO & Ryan Keeling, CIO04:46 - Enterprise engagements06:27 - Strategy Acceleration Nick Roberts, CFO12:26 - Revenue Growth14:33 - P&L Statement Nick Roberts, CFO & Ryan Keeling, CIO17:06 - Growth and scale investement Ryan Keeling, CIO21:08 - DXRX Platform28:24 - Outlook Diaceutics provide the world's leading pharma and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform. DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.